Travis Steed
Stock Analyst at Barclays
(2.89)
# 1,527
Out of 4,826 analysts
85
Total ratings
45.59%
Success rate
7.04%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $167.00 | +56.29% | 8 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $294.17 | +8.78% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $132.60 | +13.12% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $66.89 | +27.07% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $75.20 | +19.68% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $16.12 | +98.51% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $30.43 | +47.88% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $12.05 | +273.44% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $381.56 | -17.44% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $258.83 | +13.97% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $16.77 | -4.59% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $21.33 | +54.71% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $90.48 | +76.83% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $531.82 | -40.77% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $3.60 | +122.22% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $12.52 | +99.68% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.25 | +496.49% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $80.25 | +55.76% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $83.35 | +73.97% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $104.24 | -51.07% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $56.92 | +207.45% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $13.28 | +306.63% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $107.98 | -79.63% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $167.00
Upside: +56.29%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $294.17
Upside: +8.78%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $132.60
Upside: +13.12%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $66.89
Upside: +27.07%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $75.20
Upside: +19.68%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $16.12
Upside: +98.51%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $30.43
Upside: +47.88%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $12.05
Upside: +273.44%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $381.56
Upside: -17.44%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $258.83
Upside: +13.97%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $16.77
Upside: -4.59%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $21.33
Upside: +54.71%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $90.48
Upside: +76.83%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $531.82
Upside: -40.77%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $3.60
Upside: +122.22%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $12.52
Upside: +99.68%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.25
Upside: +496.49%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $80.25
Upside: +55.76%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $83.35
Upside: +73.97%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $104.24
Upside: -51.07%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $56.92
Upside: +207.45%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $13.28
Upside: +306.63%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $107.98
Upside: -79.63%